Tag: Fda drug recall

In July 2025, the U.S. Food and Drug Administration (FDA) upgraded a significant recall involving more than 160,000 bottles of Levothyroxine Sodium, clarifying the answer to the question, "**What thyroid medicine is being recalled?**". This was classified as a Class II recall, indicating the product may cause temporary or medically reversible adverse health consequences.

As of September 2024, over 3 million tubes of REFRESH P.M. and REFRESH Lacri-Lube lubricant eye ointments have been recalled by their manufacturer, Abbvie (Allergan), due to a potential issue with the tube seals. This was a Class II recall, meaning the product use may cause temporary or medically reversible adverse health consequences. Understanding which REFRESH eye drops are being recalled is critical for consumers to ensure their safety and protect their eye health.